Cargando…

Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, with clinical features of high metastatic potential, susceptibility to relapse, and poor prognosis. TNBC lacks the expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth fa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Munkácsy, Gyöngyi, Santarpia, Libero, Győrffy, Balázs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138520/ https://www.ncbi.nlm.nih.gov/pubmed/37108109 http://dx.doi.org/10.3390/ijms24086945

Ejemplares similares

Gene Expression Profiling in Early Breast Cancer—Patient Stratification Based on Molecular and Tumor Microenvironment Features
por: Munkácsy, Gyöngyi, et al.
Publicado: (2022)

Pancancer survival analysis of cancer hallmark genes
por: Nagy, Ádám, et al.
Publicado: (2021)

Metabolic reprogramming in triple-negative breast cancer
por: Wang, Zhanyu, et al.
Publicado: (2020)

Independent validation of induced overexpression efficiency across 242 experiments shows a success rate of 39%
por: Munkácsy, Gyöngyi, et al.
Publicado: (2019)

Comparison of scientometric achievements at PhD and scientific output ten years later for 4,790 academic researchers
por: Munkácsy, Gyöngyi, et al.
Publicado: (2022)

Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting
por: Pongor, Lőrinc S., et al.
Publicado: (2020)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients
por: Bottai, Giulia, et al.
Publicado: (2016)

Proteotranscriptomic Discrimination of Tumor and Normal Tissues in Renal Cell Carcinoma
por: Bartha, Áron, et al.
Publicado: (2023)

TP53 mutation hits energy metabolism and increases glycolysis in breast cancer
por: Harami-Papp, Hajnalka, et al.
Publicado: (2016)

DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer
por: Menyhart, Otília, et al.
Publicado: (2017)

Integrated MicroRNA–mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer
por: Bottai, Giulia, et al.
Publicado: (2017)

Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer
por: Iorio, Egidio, et al.
Publicado: (2016)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
por: Li, Chia-Jung, et al.
Publicado: (2021)

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
por: Poddar, Arpita, et al.
Publicado: (2022)

MIG‐6 is essential for promoting glucose metabolic reprogramming and tumor growth in triple‐negative breast cancer
por: He, Jiabei, et al.
Publicado: (2021)

Short term starvation potentiates the efficacy of chemotherapy in triple negative breast cancer via metabolic reprogramming
por: Pateras, Ioannis S., et al.
Publicado: (2023)

Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments
por: Munkácsy, Gyöngyi, et al.
Publicado: (2016)

The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer
por: Johnson, Rebecca, et al.
Publicado: (2013)

Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential
por: McHenry, Peter R., et al.
Publicado: (2023)

Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer
por: O’Flanagan, Ciara H., et al.
Publicado: (2017)

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
por: Győrffy, Balázs, et al.
Publicado: (2018)

Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment
por: Adinew, Getinet M., et al.
Publicado: (2021)

Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications
por: Gandhi, Nishant, et al.
Publicado: (2019)

Therapeutic landscape in mutational triple negative breast cancer
por: Shi, Yaqin, et al.
Publicado: (2018)

MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer
por: Goode, Gennifer, et al.
Publicado: (2017)

Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype
por: Shao, Fangyuan, et al.
Publicado: (2017)

On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer
por: Boudghene-Stambouli, Fadia, et al.
Publicado: (2022)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
por: Jiang, Tingting, et al.
Publicado: (2016)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Novel therapeutic strategies for patients with triple-negative breast cancer
por: Zhang, Jun-Fei, et al.
Publicado: (2016)

Novel therapeutic strategies in the treatment of triple-negative breast cancer
por: Oualla, Karima, et al.
Publicado: (2017)

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
por: Cipriano, Élia, et al.
Publicado: (2021)

Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
por: Ryu, Won-Ji, et al.
Publicado: (2021)

Recent advances in therapeutic strategies for triple-negative breast cancer
por: Li, Yun, et al.
Publicado: (2022)

The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer
por: Fan, Yiqi, et al.
Publicado: (2022)

Triple-negative breast cancer and the potential for targeted therapy
por: Jhan, Jing-Ru, et al.
Publicado: (2017)

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
por: Pang, Yuyang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5cmj53b1g841cfp0l26at6optp